Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Ovarian Neoplasms

  Free Subscription


Articles published in J Clin Oncol

Retrieve available abstracts of 28 articles:
HTML format



Single Articles


    January 2022
  1. BILASH T, Walker LM
    Spare Parts: Navigating Ovarian Cancer as a Transgender Man.
    J Clin Oncol. 2022 Jan 12:JCO2101249. doi: 10.1200/JCO.21.01249.
    PubMed    


    December 2021
  2. MO DC, Ren T
    Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer.
    J Clin Oncol. 2021 Dec 10:JCO2102208. doi: 10.1200/JCO.21.02208.
    PubMed    


    September 2021
  3. PORTER RL, Matulonis UA
    Checkpoint Blockade: Not Yet NINJA Status in Ovarian Cancer.
    J Clin Oncol. 2021 Sep 16:JCO2101886. doi: 10.1200/JCO.21.01886.
    PubMed    


  4. HAMANISHI J, Takeshima N, Katsumata N, Ushijima K, et al
    Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA).
    J Clin Oncol. 2021 Sep 2:JCO2100334. doi: 10.1200/JCO.21.00334.
    PubMed     Abstract available


    May 2021
  5. ZIVANOVIC O, Chi DS, Zhou Q, Iasonos A, et al
    Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study.
    J Clin Oncol. 2021 May 21:JCO2100605. doi: 10.1200/JCO.21.00605.
    PubMed     Abstract available


    April 2021
  6. MOORE KN, Bookman M, Sehouli J, Miller A, et al
    Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).
    J Clin Oncol. 2021 Apr 23:JCO2100306. doi: 10.1200/JCO.21.00306.
    PubMed     Abstract available


  7. KONSTANTINOPOULOS PA, Cannistra SA
    Immune Checkpoint Inhibitors in Ovarian Cancer: Can We Bridge the Gap Between IMagynation and Reality?
    J Clin Oncol. 2021 Apr 23:JCO2100571. doi: 10.1200/JCO.21.00571.
    PubMed    


    February 2021
  8. KURIAN AW, Ward KC, Abrahamse P, Bondarenko I, et al
    Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019.
    J Clin Oncol. 2021 Feb 9:JCO2002785. doi: 10.1200/JCO.20.02785.
    PubMed     Abstract available


    November 2020
  9. MONK BJ, Grisham RN, Banerjee S, Kalbacher E, et al
    MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
    J Clin Oncol. 2020;38:3753-3762.
    PubMed     Abstract available


    October 2020
  10. OZA AM, Lorusso D, Aghajanian C, Oaknin A, et al
    Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma.
    J Clin Oncol. 2020;38:3494-3505.
    PubMed     Abstract available


    September 2020
  11. GERSHENSON DM, Gourley C, Paul J
    MEK Inhibitors for the Treatment of Low-Grade Serous Ovarian Cancer: Expanding Therapeutic Options for a Rare Ovarian Cancer Subtype.
    J Clin Oncol. 2020 Sep 8:JCO2002190. doi: 10.1200/JCO.20.02190.
    PubMed    


    August 2020
  12. TEW WP, Lacchetti C, Ellis A, Maxian K, et al
    PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.
    J Clin Oncol. 2020 Aug 13:JCO2001924. doi: 10.1200/JCO.20.01924.
    PubMed     Abstract available


  13. PAULINO E, Melo AC
    SOLO 3 Trial: How Do the Results Fit in With Current Evidence?
    J Clin Oncol. 2020;38:2697-2698.
    PubMed    


  14. PENSON RT, Lowe ES
    Reply to E. Paulino et al.
    J Clin Oncol. 2020;38:2698.
    PubMed    


  15. DISILVESTRO P, Colombo N, Scambia G, Kim BG, et al
    Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial.
    J Clin Oncol. 2020 Aug 4:JCO2000799. doi: 10.1200/JCO.20.00799.
    PubMed     Abstract available


    April 2020
  16. ZAMARIN D, Burger RA, Sill MW, Powell DJ Jr, et al
    Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study.
    J Clin Oncol. 2020 Apr 10:JCO1902059. doi: 10.1200/JCO.19.02059.
    PubMed     Abstract available


    March 2020
  17. BEEBE-DIMMER JL, Kapron AL, Fraser AM, Smith KR, et al
    Risk of Prostate Cancer Associated With Familial and Hereditary Cancer Syndromes.
    J Clin Oncol. 2020 Mar 24:JCO1902808. doi: 10.1200/JCO.19.02808.
    PubMed     Abstract available


  18. YANG X, Leslie G, Doroszuk A, Schneider S, et al
    Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families.
    J Clin Oncol. 2020;38:674-685.
    PubMed     Abstract available


    February 2020
  19. PENSON RT, Valencia RV, Cibula D, Colombo N, et al
    Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial.
    J Clin Oncol. 2020 Feb 19:JCO1902745. doi: 10.1200/JCO.19.02745.
    PubMed     Abstract available


    January 2020
  20. KONSTANTINOPOULOS PA, Norquist B, Lacchetti C, Armstrong D, et al
    Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
    J Clin Oncol. 2020 Jan 27:JCO1902960. doi: 10.1200/JCO.19.02960.
    PubMed     Abstract available


  21. TEWARI KS, Monk BJ, Burger RA
    Reply to Farolfi et al and Haines et al.
    J Clin Oncol. 2020;38:173-174.
    PubMed    


    November 2019
  22. HAINES IE, Gabor Miklos GL
    Bevacizumab Moonshots: An Important Outcome From the Latest Ovarian Cancer Mission.
    J Clin Oncol. 2019 Nov 7:JCO1901912. doi: 10.1200/JCO.19.01912.
    PubMed    


  23. FAROLFI A, Lorusso D, Pignata S, De Giorgi U, et al
    Bevacizumab As Maintenance Treatment in Patients With Ovarian Cancer: Wait for BRCA Testing.
    J Clin Oncol. 2019 Nov 7:JCO1902055. doi: 10.1200/JCO.19.02055.
    PubMed    


    September 2019
  24. DE JAEGHERE EA, Gremonprez FB, Tummers PG, Willaert WC, et al
    Treatment of Ovarian Cancer With Intraperitoneal Platinum: Heating Up the Debate.
    J Clin Oncol. 2019 Sep 25:JCO1901179. doi: 10.1200/JCO.19.01179.
    PubMed    


  25. TOMAO F, Benedetti Panici P, Tomao S
    Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: Old and Novel Questions.
    J Clin Oncol. 2019 Sep 25:JCO1901163. doi: 10.1200/JCO.19.01163.
    PubMed    


    April 2019
  26. BAE JM, Chung KY, Yun SJ, Kim H, et al
    Markedly Reduced Risk of Internal Malignancies in Patients With Vitiligo: A Nationwide Population-Based Cohort Study.
    J Clin Oncol. 2019;37:903-911.
    PubMed     Abstract available


    February 2019
  27. FONSECA A, Xia C, Lorenzo AJ, Krailo M, et al
    Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children's Oncology Group.
    J Clin Oncol. 2019;37:396-402.
    PubMed     Abstract available


    January 2019
  28. BOULAY RM
    The Boy I Never Knew.
    J Clin Oncol. 2019;37:254-255.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: